Submit your Defective Drugs claim details for a free, no obligation case review.
Get Started:
drug_recall fen_phenFDA Withdrawal of Fenfluramine and Dexfenfluramine (Fen Phen) Announcement
FOR IMMEDIATE RELEASE
September 15, 1997
The Food and Drug Administration, acting on new evidence about significant side effects associated with fenfluramine and dexfenfluramine, has asked the manufacturers to voluntarily withdraw both treatments for obesity from the market. Dexfenfluramine is manufactured for Interneuron Pharmaceuticals and marketed under the name of Redux by Wyeth-Ayerst Laboratories, a subsidiary of American Home Products Corp. of Madison, N.J., which also manufactures and markets fenfluramine under the brand name Pondimin. Both companies have agreed to voluntarily withdraw their drugs. The FDA is not requesting the withdrawal of phentermine, the third widely used medication for obesity.
Fen-phen is the common name for the combination of the drugs pondimin
(fenfluramine), redux (dexfenfluramine) and phentermine
The action is based on new findings from doctors who have evaluated patients
taking these two drugs with echocardiograms, a special procedure that
can test the functioning of heart valves. These findings indicate that
approximately 30 percent of patients who were evaluated had abnormal echocardiograms,
even though they had no symptoms. This is a much higher than expected
percentage of abnormal test results.
“These findings call for prompt action,” said Michael A. Friedman, M.D., the Lead Deputy Commissioner of the FDA. “The data we have obtained indicate that fenfluramine, and the chemically closely related dexfenfluramine, present an unacceptable risk at this time to patients who take them.”
FDA recommends that patients using either of these products stop taking them. Users of these two products should contact their doctors to discuss their treatment.
These new findings suggest fenfluramine and dexfenfluramine are the likely cause of heart valve problems of the type that prompted FDA’s two earlier warnings concerning “fen-phen,” a combination of fenfluramine and phentermine. “Fen-phen” has been widely used off-label in recent years for the long-term management of obesity.
In July, researchers at the Mayo Clinic and Mayo Foundation reported 24 cases of rare valvular disease in women who took the “fen-phen” combination therapy. FDA alerted medical doctors that it had received nine additional reports of the same type, and requested all health care professionals to report any such cases to the agency’s MedWatch program (1-800-FDA-1088/fax 1-800-FDA- 0178) or to the respective pharmaceutical manufacturers.
Subsequently, FDA received 66 additional reports of heart valve disease associated mainly with “fen-phen.” There were also reports of cases seen in patients taking only fenfluramine or dexfenfluramine. FDA requested that the manufacturers of fenfluramine and dexfenfluramine stress the potential risk to the heart in the drugs’ labeling and patient package inserts. FDA continues to receive reports of cardiac valvular disease in persons who have taken these drugs.
A federal judge approved a settlement that will cover more than 40,000 people who suffered injury from the controversial fen-phen diet pills that were pulled from the market in 1997.
This agreement, known as the seventh amendment to the Nationwide D...
Plaintiffs who decided to opt out of a class action lawsuit have been offered a comprehensive settlement offer from Wyeth for fen phen side effects.
Half of the diet drug combination fen phen, Redux and Pondimin were withdrawn in 1997...